Cytek Biosciences (CTKB) Stock: Buy, Sell, or Hold?
CTKB - Cytek Biosciences, Inc. Common Stock
$4.61
0.08 (1.77%)
▲
5d:
-1.91%
30d:
-3.56%
90d:
+14.68%
HOLD
MODERATE Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Get Alerted When CTKB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CTKB trades at premium valuation expecting 5.8% growth. Hold existing positions but don't chase. Wait for better entry.
📊 HOLD: CTKB trades at premium valuation expecting 5.8% growth. Hold existing positions but don't chase. Wait for better entry.
In-depth Analysis How we analyze
Valuation Analysis: CTKB is currently trading at $4.61, which is considered fair relative to its 30-day fair value range of $4.40 to $4.79. From a valuation perspective, the stock is trading at a premium (Forward PE: 65.9) compared to its historical average (55.6). At these levels, the market is pricing in 5.8% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CTKB is in a uptrend. The price is currently testing key support at $4.48. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 44/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $5.56 (+20.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CTKB is in a uptrend. The price is currently testing key support at $4.48. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 44/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $5.56 (+20.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$4.40 -
$4.79
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
71.4%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (44/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 20.7% below Wall St target ($5.56)
- NEUTRAL: Trading at premium valuation - market expects 5.8% growth which is achievable
- NEUTRAL: Bottoming setup forming (44/100) — watch for confirmation
Trading Range Analysis
30-Day Trading Range
$4.40 -
$4.79
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$4.48
Resistance Level
$4.81
Current Trend
Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
65.86
Wall Street Target
$5.56
(+20.7%)
Revenue Growth (YoY)
5.6%
Earnings Growth (YoY)
73.5%
Profit Margin
-39.0%
Valuation Premium vs History
+5.8% premium
PE vs Historical
65.9 vs 55.6
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+5.8%
(market-implied from PE analysis)
1-Year Target
$4.88
(+6%)
2-Year Target
$5.16
(+12%)
3-Year Target
$5.46
(+18%)
3-Yr Target (if PE normalizes)
(PE: 66→56)
PE COMPRESSION
$4.61
(0%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: September 11, 2026 9:04 PM ET
Data refreshes hourly during market hours. Next update: 10:04 PM
Data refreshes hourly during market hours. Next update: 10:04 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CTKB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$63 | 49 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$94 | 40 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$383 | 44 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$105 | 52 HOLD |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$101 | 56 HOLD |
